Anakinra is an IL-1β antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis and other autoimmune diseases to reduce clinical symptoms and suppress joint destruction [90]. Here, IL1B is linked to autoimmune disease.